Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Irinotecan with DCE-MRI in Recurrent Malignant Gliomas
NCT00352521Phase 2Completed
- Sponsor
- Duke University
- Start
- Apr 2006
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in malignant glioma, sponsored by Duke University. Primary endpoint: Correlation of the acute permeability and blood flow response (24-48 hours) with progression-free survival (PFS) at 1 year. Started Apr 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00352521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00352521.